Shanghai Pharmaceutical announced on the evening of December 29 that in order to further expand the development of the medical device business, the company's subsidiary company, SIHL, plans to invest 229.5 million yuan to increase its capital and acquire 51% of its equity. After the transaction, Xingquan Global's shareholding structure is: Shangshi Pharmaceutical Research and Development Co., Ltd. holds 51% of the shares, and ALLIED VISION GLOBAL LIMITED holds 49%.
Xingquan Global Co., Ltd. is an investment company registered in the Cayman Islands. Its core assets are 100% equity of Guangdong Sunnik Medical Technology Co., Ltd. held by its wholly-owned subsidiary Xingquan (Hong Kong) Co., Ltd. Sannik was established on March 29, 2011 with a registered capital of RMB 10 million. Its main business is CT tube trade and large Medical Equipment maintenance services. It is currently the largest professional third-party independent large medical equipment maintenance in China. enterprise. As of October 31, 2014, Sannik's total assets were 88.32 million yuan and net assets were 20.84 million yuan. From January to October 2014, Sannick realized sales income of 93.57 million yuan and net profit of 9.42 million yuan.
Shanghai Pharmaceuticals said that through this transaction, Shanghai Pharmaceutical will further expand its medical device business category and transform into a medical service industry to create the core competitiveness of the medical device business.
In recent years, the demand for medical devices has been rising, and there is an increasingly wide market in the pharmaceutical industry. Shanghai medical related people have also publicly stated that medical devices are a market with great potential. Although the current proportion of the company's medical device business is not large, the company is very concerned and incorporates this into the three-year development plan of Shanghai Pharmaceutical.
It is understood that Shanghai Medical's medical device business was mainly concentrated in Shanghai Medical Devices Co., Ltd., its net profit in 2013 was 38.28 million yuan, accounting for 0.5% of Shanghai Pharmaceutical's net profit.
covid19
Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesia.com